Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
You may also be interested in...
Medtech Insight has spoken to several companies aiming to release devices that will replace current blood glucose monitors via disruptive, innovative technologies.
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
The document discusses feasibility studies on devices that use therapies like neurostimulation or changes to the small intestine to better control blood glucose levels in people with type 2 diabetes.